SHANGHAI, June 29 /PRNewswire-Asia/ -- Sundia MediTech Company, a leading integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China announced today that Dr. Tong Xu has been appointed Vice President of Process Chemistry Services.
Prior to joining Sundia, Dr. Xu worked at La Jolla Pharmaceutical Company, an R&D based biotech company in San Diego, USA for 12 years. At La Jolla Pharmaceutical Company, Dr. Xu rose through the ranks from Research Scientist, to Manager, Senior Manager, and Associate Director of Process Development. Through this career path, he accumulated extensive experience in developing and managing process chemistry programs. His accomplishments include directing process development effort of Riquent(R) at clinical phase III and pre-commercialization stage.
"I am very pleased to welcome Dr. Xu to join Sundia. He is not only an outstanding scientist and research fellow, but also an experienced business manager," said Dr. Xiaochuan Wang, Chairman and CEO of Sundia. "Dr. Xu led the effort in his previous employment to search, select, negotiate and qualify CRO service providers in GLP and cGMP production of raw materials, starting materials, and API intermediates. This experience is very valuable for his new role to lead process chemistry CRO services at Sundia."
Dr. Xu received his bachelor's degree in Chemistry from Nankai University,
and his Ph.D. degree in Organic Chemistry from the
About Sundia: Sundia MediTech Company is a leading integrated pharmaceutical contract research organization (CRO) company based in Shanghai, China, to provide R&D outsourcing services to biotech and pharmaceutical companies worldwide, ranging from early hit screening, biological service, lead optimization, DMPK, candidate preclinical development, formulation development, API manufacture, and regulatory submission. For more information, please visit http://www.sundia.com .
|SOURCE Sundia MediTech Company|
Copyright©2009 PR Newswire.
All rights reserved